Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

Despite the approval of second-generation antiobesity medications, metabolic and bariatric surgery (MBS) use among U.S.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

Hidden fat stored deep within muscles can significantly raise your risk of heart disease, heart attacks, and heart failure, ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...